News ReleaseView printer-friendly version
Quidel Third Quarter 2004 Results Conference Call Alert
SAN DIEGO--(BUSINESS WIRE)--Oct. 14, 2004--Quidel Corporation (Nasdaq:QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, will release third quarter 2004 financial results after market close on Wednesday, October 27, 2004.
Caren L. Mason, president and chief executive officer, and Paul E. Landers, senior vice president and chief financial officer, will be hosting an investment community conference call beginning at 5:00 p.m. ET (2:00 p.m. PT) on Wednesday, October 27, 2004, to discuss those results and to answer questions.
To participate in the live call by telephone, please dial 888-803-7396 from the U.S., or for international callers, please dial 706-634-1052.
Those interested in listening to the conference call live via the Internet may do so by visiting the Company's Web site at www.quidel.com. To listen to the live call, please go to the Web site 15 minutes prior to its start to register, download and install the necessary audio software.
A replay will be available on Quidel's Web site for 14 days. A telephone replay will be available for 48 hours by dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers, and entering reservation number 1564954.
Quidel Corporation is a global company dedicated to helping women and their families live healthy lives through the discovery, development, manufacture and marketing of point-of-care (POC) rapid diagnostic tests that detect medical conditions and illnesses. Quidel's products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions in areas including reproduction, upper respiratory infections and other clinical conditions. Quidel's diagnostic tests include pregnancy, infectious diseases, including influenza A and B, Strep throat, H. pylori, chlamydia, infectious mononucleosis and infectious vaginitis. Quidel's products are sold to healthcare professionals for use in physician offices, clinical laboratories and to consumers through several distribution partners. For more information, please visit www.quidel.com.
CONTACT: Quidel Corporation
Paul E. Landers, 858-552-7962
Lippert/Heilshorn & Associates
Ina McGuinness (email@example.com)
Bruce Voss (firstname.lastname@example.org)
SOURCE: Quidel Corporation